COIOSDeep risk insights through multi-disciplinary research across the globe
white and black plastic bottles
Item confirms Peer-reviewed Added

GLP-1 drugs cut weight by 6.7 kg in patients taking antipsychotics

A meta-analysis of eight randomised trials in 664 patients taking antipsychotics found that GLP-1 receptor agonists reduced body weight by 6.74 kg, alongside more nausea, vomiting and constipation.

Eight randomised trials of 664 patients with schizophrenia spectrum or bipolar disorder on antipsychotics were pooled to assess added GLP-1 receptor agonists. Body weight fell by 6.74 kg against control, and HbA1c by 0.61 percentage points. Overall and serious adverse events did not differ, although nausea, vomiting and constipation were more frequent on GLP-1 treatment.

Why it is interesting: Pooled trial evidence in a group with reduced life expectancy, on weight and blood glucose rather than deaths.

Source
Journal of Psychopharmacology, 16 September 2026
Paper
Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials
Authors
Moubarak ES, Elgendy MS, Elkoumi O, Ibrahim AA, Manasrah A, Ahmad J et al.
DOI
10.1177/02698811261478625
Type
Peer-reviewed article
Design
Systematic review and meta-analysis of 8 randomised trials, 664 patients, searched to May 2026
Verdict
Confirms prior evidence
Driver
Obesity, diabetes and GLP-1

Other drivers in Health today